Immunotherapy has revolutionized the treatment in metastatic melanoma, but alternative
biomarkers that are economical, simple and reliable still need to be clarified. In this study …

Introduction Recently, the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) has
been widely evaluated in many cancers. Here we assessed the prognostic value of …

Background: A number of studies have investigated the prognostic impact of the neutrophil-
to-lymphocyte ratio (NLR) in patients with melanoma but the results were controversial …

Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio
(NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including …

Background An elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poor
survival in patients with cancer, including those who receive immunotherapies. The authors …

Background: Previous studies have suggested that an elevated pre-treatment neutrophil-to-
lymphocyte ratio (NLR) is associated with worse outcomes in patients with a variety of …

Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and
duration. Upfront identification of patients who are more likely or unlikely to benefit from …

Neutrophil-to-lymphocyte ratio is a strong predictor for overall survival and disease free
survival in many cancers. Our study is the first investigation aiming to determine the …

The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with
prognosis in many malignancies including metastatic melanoma. However, it has not been …

Background Previous studies have suggested that an elevated baseline neutrophil-to-
lymphocyte ratio (BLNLR) and elevated relative change of NLR (ΔNLR%) is associated with …